What is a PET-CT Fluorodopa Scan?
A PET-CT fluorodopa (18F-FDOPA) scan is a nuclear medicine imaging procedure that uses a radioactive tracer (fluorine-18 labeled dihydroxyphenylalanine) to visualize specific metabolic pathways in the body, primarily dopaminergic nerve terminals in the brain and neuroendocrine tumors throughout the body.
Primary Clinical Applications
The FDA-approved indication for 18F-FDOPA PET is to visualize dopaminergic nerve terminals in the striatum for evaluating adult patients with suspected Parkinsonian syndromes 1. This serves as an adjunct to other diagnostic evaluations when differentiating Parkinson's disease from other causes of tremor and parkinsonism 2.
Beyond this FDA-approved use, 18F-FDOPA PET/CT has demonstrated significant utility in several other clinical scenarios:
Neuroendocrine Tumors
- Neuroblastoma: Shows superior diagnostic performance compared to standard MIBG scintigraphy, detecting significantly more lesions in 7 out of 10 studies 3. The scan is particularly valuable for staging and detecting disease relapse in high-risk neuroblastoma patients 3.
- Pheochromocytomas and paragangliomas: Useful for confirmation, staging, and follow-up 4, 5
- Carcinoid tumors: Greater sensitivity than somatostatin receptor scintigraphy 5
- Medullary thyroid cancer: Good modality for detecting persistent and residual disease 5
Congenital Hyperinsulinism
Excellent for distinguishing focal from diffuse disease in children with congenital hyperinsulinism (CHI), allowing precise preoperative localization 6, 7. Detection rate is significantly higher in patients with ABCC8 paternal monoallelic recessive gene mutations 7.
Brain Tumors
Valuable in managing low-grade and high-grade gliomas, with higher uptake associated with IDH-mutant gliomas and LAT1 expression 8, 9.
How the Scan Works
Mechanism: 18F-FDOPA is taken up into cells via the neutral amino acid transporter (LAT1/4F2hc) 5. It traces a very specific metabolic pathway with a precise biodistribution pattern 4.
Procedure:
- Dose: 185 MBq (5 mCi) administered intravenously over 1 minute for adults 1; 2-5 MBq/kg for pediatric patients 3
- Preparation: Fasting is required 3; patients should void immediately before imaging 1
- Timing: Imaging begins approximately 80 minutes post-administration, with scanning from 80-100 minutes 1
- Duration: 15-20 minutes for standard scanners 3; as little as 2 minutes with newer long axial field-of-view devices 3
Key Advantages Over Traditional Imaging
Compared to MIBG scintigraphy (the traditional standard for neuroblastoma):
- Single-day examination versus 2-day protocol 3
- Superior spatial resolution 3
- Faster acquisition (1 hour vs 24+ hours) 3
- Less need for sedation in pediatric patients 3
- Better lesion detection, particularly in disease relapse settings 3
Normal Distribution and Pitfalls
Physiological uptake is seen in:
- Basal ganglia (brain)
- Liver (greatest activity)
- Pancreas
- Other exocrine glands
- Urinary system 10
Common pitfalls: Incidental uptake occurs in approximately 5.5% of patients, which may represent inflammatory tissue or benign tumors 10. Correlation with clinical history, physical examination, laboratory tests, CT, MRI, and histology is essential for optimal diagnosis 10.
Radiation Safety
Use the smallest dose necessary for imaging with proper radiation shielding 1. For lactating women, advise pumping and discarding breastmilk for at least 24 hours (12 half-lives) after administration 1.
Clinical Impact
In movement disorder clinics, 18F-FDOPA PET altered provisional diagnosis in 37.9% of patients and changed clinical management in 48.4% of patients 2. In neuroblastoma, PET results influenced patient management or therapeutic strategy in approximately 30% of cases 3.